{"id":2569,"date":"2024-06-12T12:11:00","date_gmt":"2024-06-12T10:11:00","guid":{"rendered":"https:\/\/web.infn.it\/TechTransfer\/?p=2569"},"modified":"2025-02-10T12:04:44","modified_gmt":"2025-02-10T11:04:44","slug":"sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can","status":"publish","type":"post","link":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/","title":{"rendered":"Sviluppo di terapie oncologiche innovative:                                                                               al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p>Scoprire e\u00a0sviluppare nuove terapie antitumorali mediante piccole molecole note come Folding Interfering Degraders (FID), che interrompono il corretto ripiegamento delle proteine bersaglio,  distruggendole. Questo l&#8217;obiettivo dell&#8217;accordo di ricerca tra <a href=\"https:\/\/www.sibyllabiotech.it\/\">Sibylla Biotech<\/a>, una giovane azienda italiana spin-off dell\u2019INFN, e la <a href=\"https:\/\/www.mdanderson.org\/\">MD Anderson Cancer Center <\/a>dell\u2019Universit\u00e0 del Texas, uno dei principali punti di riferimento mondiali nella cura del cancro.<\/p>\n\n\n\n<p>L\u2019accordo di ricerca in questione ha una notevole valenza in quanto testimonia l\u2019impatto di Sibylla Biotech, una giovane azienda nata da un&#8217;invenzione scaturita dalla ricerca nell\u2019ambito della fisica teorica dell\u2019INFN che in pochi anni ha seguito un importante percorso di crescita sia economica che scientifica al punto di condurre attivit\u00e0 di ricerca congiunte con l&#8217;MD Anderson Cancer Center, struttura ospedaliera multicentrica dell&#8217;Universit\u00e0 del Texas e considerata il miglior centro ospedaliero statunitense nel campo della cura, la ricerca, l&#8217;educazione e la prevenzione delle malattie oncologiche.\u00a0<\/p>\n\n\n\n<p>In base all\u2019accordo, Sibylla e MD Anderson condurranno lavori di scoperta e sviluppo dall\u2019identificazione del bersaglio, alla nomina di farmaci candidati su proteine selezionate, con la possibilit\u00e0, nel caso, di continuare ulteriormente lo sviluppo preclinico e clinico. La collaborazione unisce la Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT), tecnologia innovativa sviluppata da INFN, Universit\u00e0 d Trento e di Perugia e Telethon, che sfrutta un approccio computazionale con l\u2019esperienza e le capacit\u00e0 di sviluppo di farmaci della divisione Therapeutics Discovery di MD Anderson.&nbsp;<\/p>\n\n\n\n<p>La tecnologia proprietaria PPI-FIT di Sibylla sar\u00e0 utilizzata per scoprire e sviluppare FID, piccole molecole che inducono la degradazione delle proteine bersaglio interferendo con il loro percorso di ripiegamento. In particolare, PPI-FIT pu\u00f2 essere applicato a proteine bersaglio oncogeniche attualmente considerate \u201cnon trattabili\u201d.&nbsp;&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scoprire e\u00a0sviluppare nuove terapie antitumorali mediante piccole molecole note come Folding Interfering Degraders (FID), che interrompono il corretto ripiegamento delle proteine bersaglio, distruggendole. Questo l&#8217;obiettivo dell&#8217;accordo di ricerca tra Sibylla Biotech, una giovane azienda italiana spin-off dell\u2019INFN, e la MD Anderson Cancer Center dell\u2019Universit\u00e0 del&#8230;<\/p>\n","protected":false},"author":4,"featured_media":2575,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[161],"tags":[],"class_list":["post-2569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-02-dal-laboratorio-al-mondo"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sviluppo di terapie oncologiche innovative:                                        al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center - TechTransfer INFN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sviluppo di terapie oncologiche innovative:                                        al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center - TechTransfer INFN\" \/>\n<meta property=\"og:description\" content=\"Scoprire e\u00a0sviluppare nuove terapie antitumorali mediante piccole molecole note come Folding Interfering Degraders (FID), che interrompono il corretto ripiegamento delle proteine bersaglio, distruggendole. Questo l&#8217;obiettivo dell&#8217;accordo di ricerca tra Sibylla Biotech, una giovane azienda italiana spin-off dell\u2019INFN, e la MD Anderson Cancer Center dell\u2019Universit\u00e0 del...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/\" \/>\n<meta property=\"og:site_name\" content=\"TechTransfer INFN\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IstitutoFisicaNucleare\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-12T10:11:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-10T11:04:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/web.infn.it\/TechTransfer\/wp-content\/uploads\/2024\/07\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Diego Tonini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Diego Tonini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/\"},\"author\":{\"name\":\"Diego Tonini\",\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/#\\\/schema\\\/person\\\/00b4391eec00d565f3a1d39921d81aa9\"},\"headline\":\"Sviluppo di terapie oncologiche innovative: al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center\",\"datePublished\":\"2024-06-12T10:11:00+00:00\",\"dateModified\":\"2025-02-10T11:04:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/\"},\"wordCount\":304,\"image\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg\",\"articleSection\":[\"Dal laboratorio al mondo\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/\",\"url\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/\",\"name\":\"Sviluppo di terapie oncologiche innovative: al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center - TechTransfer INFN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg\",\"datePublished\":\"2024-06-12T10:11:00+00:00\",\"dateModified\":\"2025-02-10T11:04:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/#\\\/schema\\\/person\\\/00b4391eec00d565f3a1d39921d81aa9\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\\\/#primaryimage\",\"url\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg\",\"width\":2560,\"height\":1440,\"caption\":\"loghi Sibylla e MD Anderson Cancer Center su sfondo blu\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/#website\",\"url\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/\",\"name\":\"INFN Trasferimento Tecnologico\",\"description\":\"Trasferimento Tecnologico | Istituto Nazionale Fisica Nucleare\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/#\\\/schema\\\/person\\\/00b4391eec00d565f3a1d39921d81aa9\",\"name\":\"Diego Tonini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b852ae18da0b889e31c80cff41b73e37a1b074dc5b136acc1999c593d201828f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b852ae18da0b889e31c80cff41b73e37a1b074dc5b136acc1999c593d201828f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b852ae18da0b889e31c80cff41b73e37a1b074dc5b136acc1999c593d201828f?s=96&d=mm&r=g\",\"caption\":\"Diego Tonini\"},\"url\":\"https:\\\/\\\/web.infn.it\\\/TechTransfer\\\/author\\\/diego\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sviluppo di terapie oncologiche innovative:                                        al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center - TechTransfer INFN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/","og_locale":"it_IT","og_type":"article","og_title":"Sviluppo di terapie oncologiche innovative:                                        al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center - TechTransfer INFN","og_description":"Scoprire e\u00a0sviluppare nuove terapie antitumorali mediante piccole molecole note come Folding Interfering Degraders (FID), che interrompono il corretto ripiegamento delle proteine bersaglio, distruggendole. Questo l&#8217;obiettivo dell&#8217;accordo di ricerca tra Sibylla Biotech, una giovane azienda italiana spin-off dell\u2019INFN, e la MD Anderson Cancer Center dell\u2019Universit\u00e0 del...","og_url":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/","og_site_name":"TechTransfer INFN","article_publisher":"https:\/\/www.facebook.com\/IstitutoFisicaNucleare\/","article_published_time":"2024-06-12T10:11:00+00:00","article_modified_time":"2025-02-10T11:04:44+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/web.infn.it\/TechTransfer\/wp-content\/uploads\/2024\/07\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg","type":"image\/jpeg"}],"author":"Diego Tonini","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Diego Tonini","Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/#article","isPartOf":{"@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/"},"author":{"name":"Diego Tonini","@id":"https:\/\/web.infn.it\/TechTransfer\/#\/schema\/person\/00b4391eec00d565f3a1d39921d81aa9"},"headline":"Sviluppo di terapie oncologiche innovative: al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center","datePublished":"2024-06-12T10:11:00+00:00","dateModified":"2025-02-10T11:04:44+00:00","mainEntityOfPage":{"@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/"},"wordCount":304,"image":{"@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/#primaryimage"},"thumbnailUrl":"https:\/\/web.infn.it\/TechTransfer\/wp-content\/uploads\/2024\/07\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg","articleSection":["Dal laboratorio al mondo"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/","url":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/","name":"Sviluppo di terapie oncologiche innovative: al via la collaborazione strategica tra Sibylla Biotech e MD Anderson\u00a0Cancer Center - TechTransfer INFN","isPartOf":{"@id":"https:\/\/web.infn.it\/TechTransfer\/#website"},"primaryImageOfPage":{"@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/#primaryimage"},"image":{"@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/#primaryimage"},"thumbnailUrl":"https:\/\/web.infn.it\/TechTransfer\/wp-content\/uploads\/2024\/07\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg","datePublished":"2024-06-12T10:11:00+00:00","dateModified":"2025-02-10T11:04:44+00:00","author":{"@id":"https:\/\/web.infn.it\/TechTransfer\/#\/schema\/person\/00b4391eec00d565f3a1d39921d81aa9"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/web.infn.it\/TechTransfer\/sviluppo-di-terapie-oncologiche-innovative-al-via-la-collaborazione-strategica-tra-sibylla-biotech-e-md-anderson-can\/#primaryimage","url":"https:\/\/web.infn.it\/TechTransfer\/wp-content\/uploads\/2024\/07\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg","contentUrl":"https:\/\/web.infn.it\/TechTransfer\/wp-content\/uploads\/2024\/07\/5MkupSibyllaxMDAnderson-pdf-scaled.jpg","width":2560,"height":1440,"caption":"loghi Sibylla e MD Anderson Cancer Center su sfondo blu"},{"@type":"WebSite","@id":"https:\/\/web.infn.it\/TechTransfer\/#website","url":"https:\/\/web.infn.it\/TechTransfer\/","name":"INFN Trasferimento Tecnologico","description":"Trasferimento Tecnologico | Istituto Nazionale Fisica Nucleare","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/web.infn.it\/TechTransfer\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/web.infn.it\/TechTransfer\/#\/schema\/person\/00b4391eec00d565f3a1d39921d81aa9","name":"Diego Tonini","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/b852ae18da0b889e31c80cff41b73e37a1b074dc5b136acc1999c593d201828f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b852ae18da0b889e31c80cff41b73e37a1b074dc5b136acc1999c593d201828f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b852ae18da0b889e31c80cff41b73e37a1b074dc5b136acc1999c593d201828f?s=96&d=mm&r=g","caption":"Diego Tonini"},"url":"https:\/\/web.infn.it\/TechTransfer\/author\/diego\/"}]}},"_links":{"self":[{"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/posts\/2569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/comments?post=2569"}],"version-history":[{"count":4,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/posts\/2569\/revisions"}],"predecessor-version":[{"id":2573,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/posts\/2569\/revisions\/2573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/media\/2575"}],"wp:attachment":[{"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/media?parent=2569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/categories?post=2569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/web.infn.it\/TechTransfer\/wp-json\/wp\/v2\/tags?post=2569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}